PortfoliosLab logoPortfoliosLab logo
IONS vs. ABBV
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

IONS vs. ABBV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ionis Pharmaceuticals, Inc. (IONS) and AbbVie Inc. (ABBV). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, IONS achieves a -3.94% return, which is significantly lower than ABBV's 4.43% return. Over the past 10 years, IONS has underperformed ABBV with an annualized return of 13.21%, while ABBV has yielded a comparatively higher 19.47% annualized return.


IONS

1D
0.13%
1M
0.57%
YTD
-3.94%
6M
-5.40%
1Y
101.73%
3Y*
24.22%
5Y*
14.60%
10Y*
13.21%

ABBV

1D
2.07%
1M
8.84%
YTD
4.43%
6M
4.29%
1Y
31.92%
3Y*
24.36%
5Y*
19.80%
10Y*
19.47%
*Multi-year figures are annualized to reflect compound growth (CAGR)

IONS vs. ABBV - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
IONS
Ionis Pharmaceuticals, Inc.
-3.94%126.29%-30.90%33.94%24.12%-46.18%-6.41%11.75%7.48%5.16%
ABBV
AbbVie Inc.
4.43%33.08%18.86%-0.23%24.01%32.43%27.72%1.47%-0.96%60.07%

Correlation

The correlation between IONS and ABBV is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.32

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (5Y)
Calculated over the trailing 5-year period

0.19

Correlation (10Y)
Calculated over the trailing 10-year period

0.25

Correlation (All Time)
Calculated using the full available price history since Jan 2, 2013

0.28

The correlation between IONS and ABBV shifts across timeframes, from 0.19 (5 years) to 0.32 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

IONS:

$12.53B

ABBV:

$416.46B

EPS

IONS:

-$1.95

ABBV:

$2.05

PS Ratio

IONS:

12.03

ABBV:

6.63

PB Ratio

IONS:

25.50

ABBV:

15.14

Total Revenue (TTM)

IONS:

$1.06B

ABBV:

$62.82B

Gross Profit (TTM)

IONS:

$1.04B

ABBV:

$46.15B

EBITDA (TTM)

IONS:

$4.54B

ABBV:

$17.96B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

IONS vs. ABBV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IONS
IONS Risk / Return Rank: 9393
Overall Rank
IONS Sharpe Ratio Rank: 9090
Sharpe Ratio Rank
IONS Sortino Ratio Rank: 9696
Sortino Ratio Rank
IONS Omega Ratio Rank: 9393
Omega Ratio Rank
IONS Calmar Ratio Rank: 9393
Calmar Ratio Rank
IONS Martin Ratio Rank: 9191
Martin Ratio Rank

ABBV
ABBV Risk / Return Rank: 7575
Overall Rank
ABBV Sharpe Ratio Rank: 7878
Sharpe Ratio Rank
ABBV Sortino Ratio Rank: 7575
Sortino Ratio Rank
ABBV Omega Ratio Rank: 7373
Omega Ratio Rank
ABBV Calmar Ratio Rank: 7474
Calmar Ratio Rank
ABBV Martin Ratio Rank: 7373
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IONS vs. ABBV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ionis Pharmaceuticals, Inc. (IONS) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


IONSABBVDifference
Sharpe ratioReturn per unit of total volatility

+0.92

Sortino ratioReturn per unit of downside risk

+2.22

Omega ratioGain probability vs. loss probability

1.49

1.24

+0.25

Calmar ratioReturn relative to maximum drawdown

5.26

1.85

+3.41

Martin ratioReturn relative to average drawdown

12.39

4.11

+8.28

IONS vs. ABBV - Sharpe Ratio Comparison

The current IONS Sharpe Ratio is 2.19, which is higher than the ABBV Sharpe Ratio of 1.27. The chart below compares the historical Sharpe Ratios of IONS and ABBV, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

IONS vs. ABBV - Drawdown Comparison

The maximum IONS drawdown since its inception was -91.42%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for IONS and ABBV.


Loading charts...

Drawdown Indicators


IONSABBVDifference

Max Drawdown

Largest peak-to-trough decline

-91.42%

-45.09%

-46.33%

Max Drawdown (1Y)

Largest decline over 1 year

-19.45%

-17.32%

-2.13%

Max Drawdown (3Y)

Largest decline over 3 years

-52.36%

-20.74%

-31.62%

Max Drawdown (5Y)

Largest decline over 5 years

-52.36%

-21.92%

-30.44%

Max Drawdown (10Y)

Largest decline over 10 years

-70.39%

-45.09%

-25.30%

Current Drawdown

Current decline from peak

-12.15%

-1.66%

-10.49%

Average Drawdown

Average peak-to-trough decline

-52.35%

-10.70%

-41.65%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.24%

7.78%

+0.46%

Volatility

IONS vs. ABBV - Volatility Comparison

The current volatility for Ionis Pharmaceuticals, Inc. (IONS) is 6.42%, while AbbVie Inc. (ABBV) has a volatility of 9.26%. This indicates that IONS experiences smaller price fluctuations and is considered to be less risky than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


IONSABBVDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.42%

9.26%

-2.84%

Volatility (6M)

Calculated over the trailing 6-month period

20.05%

19.11%

+0.94%

Volatility (1Y)

Calculated over the trailing 1-year period

46.63%

25.23%

+21.40%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

42.20%

23.12%

+19.08%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

46.17%

25.83%

+20.34%

Dividends

IONS vs. ABBV - Dividend Comparison

IONS has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 2.87%.


PositionTTM20252024202320222021202020192018201720162015
ABBV
AbbVie Inc.
2.87%2.87%3.49%3.82%3.49%3.84%4.41%4.83%3.89%2.65%3.64%3.41%
IONS
Ionis Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

IONS vs. ABBV - Financials Comparison

This section allows you to compare key financial metrics between Ionis Pharmaceuticals, Inc. and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20222023202420252026
246.09M
15.00B
(IONS) Total Revenue
(ABBV) Total Revenue
Values in USD except per share items

IONS vs. ABBV - Profitability Comparison

The chart below illustrates the profitability comparison between Ionis Pharmaceuticals, Inc. and AbbVie Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

50.0%60.0%70.0%80.0%90.0%100.0%20222023202420252026
98.8%
83.5%
Portfolio components
IONS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ionis Pharmaceuticals, Inc. reported a gross profit of 243.11M and revenue of 246.09M. Therefore, the gross margin over that period was 98.8%.

ABBV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a gross profit of 12.53B and revenue of 15.00B. Therefore, the gross margin over that period was 83.5%.

IONS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ionis Pharmaceuticals, Inc. reported an operating income of -117.42M and revenue of 246.09M, resulting in an operating margin of -47.7%.

ABBV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported an operating income of 4.73B and revenue of 15.00B, resulting in an operating margin of 31.6%.

IONS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ionis Pharmaceuticals, Inc. reported a net income of -92.53M and revenue of 246.09M, resulting in a net margin of -37.6%.

ABBV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a net income of 699.00M and revenue of 15.00B, resulting in a net margin of 4.7%.


Frequently Asked Questions


IONS and ABBV have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ABBV has higher volatility (9.26%) compared to IONS (6.42%). In terms of maximum drawdown, IONS dropped -91.42% vs ABBV's -45.09%.

IONS currently has the higher Sharpe Ratio (2.19 vs 1.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for IONS and ABBV

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer